1. Scrip
  2. >>Business

SDP Completes Tolero Buy To Build Oncology Ahead Of Key Expiry

 
• By Ian Haydock

Sumitomo Dainippon Pharma has completed the acquisition of US specialty company Tolero for up to $780m in a move that boosts the mid-sized Japanese firm's presence in oncology ahead of a looming major patent expiry for its top-selling product.

US Japan

Sumitomo Dainippon Pharma Co. Ltd. (SDP) has paid $200m upfront for Lehi, Utah-based Tolero Pharmaceuticals Inc., and agreed further milestone payments of up to $430m related to the progress of Tolero's pipeline, plus up to $150m in post-launch commercial milestones based on net sales of commercialized Tolero-sourced products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies